北美眼痛市场，按疾病类型（伴有眼病的眼痛和不伴有原发性眼病的眼痛）、类型（诊断和治疗）、应用（结膜炎、角膜擦伤、睑缘炎、麦粒肿、虹膜炎、鼻窦炎、偏头痛、青光眼等）、给药途径（局部、眼周、眼内、口服等）、药物类型（处方药和非处方药）、人群类型（成人和老年人）、最终用户（医院、专科诊所、家庭医疗保健机构、眼科中心、门诊手术中心等）、分销渠道（直接招标、医院药房、零售药房、网上药房等）、国家（美国、加拿大、墨西哥）划分。– 行业趋势和预测到 2028 年。
市场分析与洞察：北美眼痛市场
北美眼痛市场预计将在 2021 年至 2028 年的预测期内增长。Data Bridge Market Research 分析称，在 2021 年至 2028 年的预测期内，该市场的复合年增长率为 5.7%，预计到 2028 年将达到 6.9919 亿美元。不卫生和久坐的生活方式的增加是北美眼痛市场增长的驱动力。
眼痛又称为眼痛，通常由轻微刺激引起，但很少是严重疾病的症状。大多数情况下，疼痛无需药物或进一步治疗即可缓解，并通过自身免疫系统恢复。但是，患有潜在原发性眼科疾病的眼痛需要及时治疗。眼痛通常分为两类，例如眼痛，发生在眼球表面，产生抓挠、灼热或瘙痒的感觉。它们是由人的睫毛、异物、感染或创伤引起的。通常用眼药水和外用类固醇或 NSAID 治疗眼痛。眼痛与潜在的原发性眼部疾病有关，例如结膜炎、隐形眼镜刺激、角膜擦伤、损伤、睑缘炎和麦粒肿。其他先进的治疗方法，如刺激疗法，也用于正确诊断的严重神经性眼痛。
不卫生和久坐的生活方式日益增多、眼科疾病患病率不断上升以及眼部疼痛成为北美眼部疼痛市场发展的驱动因素。人们对眼部疾病的认识不断提高以及眼部偏头痛病例的不断增加进一步促进了市场的增长。眼部治疗药物的副作用以及眼部治疗和药物的高成本制约了北美眼部疼痛市场的增长。研发活动的增加、医疗支出和可支配收入的增加以及老年人口的增长为北美眼部疼痛市场提供了机遇。缺乏眼部治疗医疗设施和严格的监管框架对北美眼部疼痛市场的增长构成了挑战。
北美眼痛市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地市场参与者的影响，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和眼痛市场情况，请联系 Data Bridge Market Research 获取分析师简报；我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美 眼痛市场范围和市场规模
北美眼痛市场根据疾病类型、类型、应用、给药途径、药物类型、人群类型、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据疾病类型，北美眼痛市场分为患有眼病的眼痛和不患有原发性眼病的眼痛。2021 年，患有眼病的眼痛部分预计将主导北美眼痛市场，因为眼痛是大多数眼病的首发症状。
- 根据类型，北美眼痛市场分为诊断和治疗。2021 年，诊断领域预计将占据市场主导地位，因为诊断领域为研究活动筹集的资金超过了诊断眼科。
- 根据应用，北美眼痛市场细分为结膜炎、角膜擦伤、眼睑炎、麦粒肿、虹膜炎、鼻窦炎、偏头痛、青光眼等。2021 年，由于疼痛初期的认知度较低，青光眼细分市场预计将占据市场主导地位。
- 根据给药途径，北美眼痛市场分为局部用药、眼周用药、眼内用药、口服用药和其他用药。2021 年，局部用药领域预计将占据市场主导地位，因为大量局部用药解决方案和产品用于眼部护理。
- 根据药物类型，北美眼部疼痛市场分为处方药和非处方药。由于政府对非处方药的监管和指导方针不断增加，处方药成为强制性规定，预计 2021 年处方药将占据市场主导地位。
- 根据人口类型，北美眼痛市场分为成人和老年人。2021 年，由于成人久坐的生活方式和习惯的增加，成人群体预计将占据市场主导地位。
- 根据最终用户，北美眼痛市场细分为医院、专科诊所、家庭医疗保健、眼科中心、门诊手术中心等。由于经济增长迅速，北美发达国家的医院数量不断增加，预计 2021 年医院部门将占据市场主导地位。
- 根据分销渠道，北美眼痛市场分为直接招标、医院药房、零售药房、网上药房等。2021 年，直接招标部分预计将占据市场主导地位，因为它们提供优质产品。
北美眼痛市场国家级分析
对北美眼痛市场进行了分析，并按上述国家、疾病类型、类型、应用、给药途径、药物类型、人口类型、最终用户和分销渠道提供了市场规模信息。
北美眼痛市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于眼科疾病病例的增加，北美地区的美国诊断部门预计将在 2021 年至 2028 年的预测期内以最高增长率增长。由于人们的不卫生习惯日益增加，加拿大的诊断部门是北美第二大主导市场。墨西哥是该地区的第三大市场，由于市场参与者和举措的数量不断增加，诊断部门在该国占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动提高了人们对眼痛治疗的认识，推动了北美 眼痛市场的市场增长
北美眼痛市场还为您提供了每个国家在特定市场增长的详细市场分析。此外，它还提供有关市场参与者的战略及其地理分布的详细信息。数据适用于 2010 年至 2019 年的历史时期。
竞争格局和北美 眼痛市场份额分析
北美眼痛市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对北美眼痛市场的关注有关。
北美眼痛市场的主要公司包括强生服务公司、辉瑞公司、EyePoint Pharmaceuticals、默克夏普和 Dohme 公司（默克公司的子公司）、Akorn Operating Company LLC、AERIE PHARMACEUTICALS、INC、Sun Pharmaceutical Industries Ltd、Bausch & Lomb Incorporated、Ocular Therapeutix、Inc.、Kala Pharmaceuticals、Novartis AG、Omeros Corporation、Allergan（AbbVie 公司旗下）、SiteOne Therapeutics、Inc.、OKYO Pharma Limited、Fera Pharmaceuticals、Vyluma、TALLC Inc.、IACTA Pharmaceuticals、Inc.、Allakos Inc.、Aldeyra Therapeutics、Inc.、Novaliq GmbH 以及其他国内公司。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
世界各地的公司也签订了许多合同和协议，加速了北美眼痛市场的发展。
例如，
- 2020 年 11 月，Allakos Inc. 参加了美国胃肠病学会 (ACG) 2020 年年度科学会议。该公司向与会客户介绍了其针对嗜酸性胃肠道疾病和其他疾病的产品。这巩固了他们在市场上的地位
- 2020 年 10 月，Aldeyra Therapeutics, Inc. 公布了其 Reproxalap 眼科溶液（0.25% 和 0.5%）的临床数据，该数据已超过第 2 阶段。他们还展示了其对过敏性结膜炎的应用。这巩固了他们在重点市场中的地位
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业等策略增强了公司在眼痛市场的影响力，也有利于公司的利润增长。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISEASE TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT OPTIONS
4.4 VOLUME OF PRESCRIPTION
5 PIPELINE ANALYSIS
6 REGIONAL SUMMARY
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 THE MIDDLE EAST AND AFRICA
7 NORTH AMERICA OCULAR PAIN MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
8.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
8.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
8.1.4 GROWING CASES OF OCULAR MIGRAINE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
8.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.3.3 INCREASING GERIATRIC POPULATION
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
9 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA OCULAR PAIN MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 OCULAR PAIN WITH EYE DISEASES
10.2.1 OCULAR PAIN WITH RED EYE
10.2.2 OCULAR PAIN WITHOUT RED EYE
10.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
10.3.1 OCULAR MIGRAINE
10.3.2 GIANT CELL ARTERITIS
10.3.3 TRIGEMINAL NEURALGIAS
10.3.4 CAVERNOUS SINUS AND SUPERIOR FISSURE PROCESSES
10.3.5 CAROTID ARTERY DISSECTION
10.3.6 CAROTIDYNIA
10.3.7 OTHERS
11 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 SENSORY TESTING
11.2.1.1 HAND LIGHT EXAMINATION
11.2.1.2 DIRECT OPHTHALMOSCOPIC EXAMINATIONS
11.2.1.3 SLIT LAMP EXAMINATION
11.2.1.4 FLUORESCEIN EXAMINATION
11.2.2 IMAGING TEST
11.2.2.1 CONFOCAL MICROSCOPY
11.2.2.2 FUNCTIONAL MRI
11.3 TREATMENT
11.3.1 LOCAL TREATMENT
11.3.1.1 TOPICAL STEROID
11.3.1.1.1 LOTEPREDNOL
11.3.1.1.2 DEXAMETHASONE
11.3.1.1.3 PREDNISOLONE
11.3.1.1.4 FLUOROMETHOLONE
11.3.1.1.5 OTHERS
11.3.1.2 NONSTEROIDAL ANTI-INFLAMMATORY (NSAID)
11.3.1.2.1 BROMFENAC
11.3.1.2.2 KETOROLAC
11.3.1.2.3 NEPAFENAC
11.3.1.2.4 DICLOFENAC
11.3.1.2.5 OTHERS
11.3.1.3 OTHERS
11.3.2 STIMULATION THERAPIES
11.3.2.1 DEEP BRAIN STIMULATION
11.3.2.2 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
11.3.2.3 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS)
11.3.2.4 SCRAMBLER THERAPY
11.3.2.5 OTHERS
11.3.3 OTHERS
12 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 GLAUCOMA
12.3 BLEPHARITIS
12.4 CONJUNCTIVITIS
12.5 CORNEAL ABRASION
12.6 STY
12.7 IRITIS
12.8 SINUSITIS
12.9 MIGRAINES
12.1 OTHERS
13 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 SOLUTION
13.2.2 GELS
13.2.3 OINTMENTS
13.2.4 OTHERS
13.3 INTRAOCULAR
13.3.1 INTRAVITREAL
13.3.2 INTRACAMERAL
13.4 PERIOCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 SUBTENON
13.4.3 PERIBULBAR
13.4.4 RETROBULBAR
13.5 ORAL
13.5.1 TABLETS
13.5.2 CAPSULE
13.5.3 OTHERS
13.6 OTHERS
14 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 PRESCRIPTION
14.3 OVER THE COUNTER
15 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 ADULTS
15.3 GERIATRIC
16 NORTH AMERICA OCULAR PAIN MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOME HEALTHCARE
16.5 OPHTHALMOLOGY CENTERS
16.6 AMBULATORY SURGICAL CENTERS
16.7 OTHERS
17 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL PHARMACY
17.5 ONLINE PHARMACY
17.6 OTHERS
18 NORTH AMERICA OCULAR PAIN MARKET, BY GEOGRAPHY
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA OCULAR PAIN MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 BAUSCH & LOMB INCORPORATED
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 NOVARTIS AG
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 OMEROS CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 AKORN OPERATING COMPANY LLC
21.5.1 COMPANY SNAPSHOT
21.5.2 COMPANY SHARE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENTS
21.6 AERIE PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALDEYRA THERAPEUTICS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 PRODUCT PORTFOLIO
21.7.3 RECENT DEVELOPMENTS
21.8 ALLAKOS INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 ALLERGAN (AN ABBVIE COMPANY)
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 EYEPOINT PHARMACEUTICALS, INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 FERA PHARMACEUTICALS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 FORMOSAPHARMA PHARMACEUTICAL INC.
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENT
21.13 IACTA PHARMACEUTICALS, INC.
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 KALA PHARMACEUTICALS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 NOVALIQ GMBH
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 OCULAR THERAPEUTIX, INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 OKYO PHARMA LIMITED
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PFIZER, INC.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 PHARMALEADS SA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 SITEONE THERAPEUTICS, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENT
21.23 SYLENTIS
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENT
21.24 TALLC INC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENT
21.25 TARSIER PHARMA LTD.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENT
21.26 VYLUMA
21.26.1 COMPANY SNAPSHOT
21.26.2 PRODUCT PORTFOLIO
21.26.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT PRODUCTS
TABLE 2 VOLUME OF PRESCRIPTION (%)
TABLE 3 NORTH AMERICA OCULAR PAIN MARKET, PIPELINE ANALYSIS
TABLE 4 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA STY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA IRITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA OVER THE COUNTER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA ADULTS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA OPHTHALMOLOGY CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 77 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 80 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 U.S. OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 U.S. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 U.S. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 U.S. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.S. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.S. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.S. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.S. OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 U.S. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 U.S. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 99 U.S. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 U.S. OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 U.S. OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 102 U.S. OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 U.S. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 CANADA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 CANADA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 106 CANADA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 CANADA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CANADA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CANADA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CANADA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CANADA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CANADA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 CANADA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 CANADA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 CANADA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 CANADA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 CANADA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 CANADA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 CANADA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 CANADA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 CANADA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CANADA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 CANADA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 124 CANADA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CANADA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 MEXICO OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 127 MEXICO OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 128 MEXICO OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 129 MEXICO OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 MEXICO DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 MEXICO SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 MEXICO IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 MEXICO TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 MEXICO LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 MEXICO TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 MEXICO STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 MEXICO OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 139 MEXICO OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 MEXICO TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 MEXICO INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 142 MEXICO PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 143 MEXICO ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 144 MEXICO OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 145 MEXICO OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 146 MEXICO OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 147 MEXICO OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA OCULAR PAIN MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE NORTH AMERICA OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA OCULAR PAIN MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA OCULAR PAIN MARKET, AND ASIA-PACIFIC IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA OCULAR PAIN MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 NORTH AMERICA AGEING POPULATION (IN MILLION)
FIGURE 17 EUROPE AGEING POPULATION (IN MILLION)
FIGURE 18 ASIA-PACIFIC AGEING POPULATION (IN MILLION)
FIGURE 19 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2020
FIGURE 20 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2020
FIGURE 28 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2020
FIGURE 36 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2020
FIGURE 40 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2019-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2020
FIGURE 44 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 48 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 49 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 50 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 NORTH AMERICA OCULAR PAIN MARKET: SNAPSHOT (2020)
FIGURE 52 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020)
FIGURE 53 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 NORTH AMERICA OCULAR PAIN MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
